KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Revenue (2016 - 2025)

Inovio Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $65343.0 for Q1 2025.

  • For Q1 2025, Revenue changed N/A year-over-year to $65343.0; the TTM value through Sep 2025 reached $182337.0, down 10.36%, while the annual FY2024 figure was $217756.0, 73.83% down from the prior year.
  • Revenue for Q1 2025 was $65343.0 at Inovio Pharmaceuticals, down from $116994.0 in the prior quarter.
  • Across five years, Revenue topped out at $9.2 million in Q3 2022 and bottomed at $65343.0 in Q1 2025.
  • The 5-year median for Revenue is $225971.0 (2023), against an average of $876809.0.
  • The largest annual shift saw Revenue surged 3038.22% in 2022 before it plummeted 95.76% in 2023.
  • A 5-year view of Revenue shows it stood at $839115.0 in 2021, then crashed by 85.14% to $124666.0 in 2022, then decreased by 17.66% to $102651.0 in 2023, then rose by 13.97% to $116994.0 in 2024, then tumbled by 44.15% to $65343.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Revenue are $65343.0 (Q1 2025), $116994.0 (Q4 2024), and $100762.0 (Q2 2024).